Abstract
Leflunomide treatment appears to offer an alternative to methotrexate and sulfasalazine and is a welcome addition to the therapeutic armamentarium for treating active RA. Leflunomide treatment for more than 12 months results in clinically meaningful improvements in disease-specific measures of physical function. The phase 3 trials have shown leflunomide to be as effective as methotrexate and sulfasalazine and an option for initial DMARD therapy. As with all new agents, the long-term safety and value of leflunomide will be determined by use in the clinic.
Original language | English (US) |
---|---|
Pages (from-to) | 1-4 |
Number of pages | 4 |
Journal | Bulletin on the Rheumatic Diseases |
Volume | 48 |
Issue number | 8 |
State | Published - 1999 |
All Science Journal Classification (ASJC) codes
- Rheumatology